We provide trade advice to complement the prevailing
expert consensus on Biomea Fusion. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Biomea Fusion dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Biomea Fusion income statement, its balance sheet, and the statement of cash flows. Potential Biomea Fusion investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Biomea Fusion investors may use each financial statement separately, they are all related. The changes in Biomea Fusion's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biomea Fusion's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Biomea Fusion
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Biomea Fusion performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Biomea Fusion shares is the value that is considered the true value of the share. If
the intrinsic value of Biomea is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Biomea Fusion. Please read more on our
fundamental analysis page.
How effective is Biomea Fusion in utilizing its assets?
Biomea Fusion reports assets on its Balance Sheet. It represents the amount of Biomea resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Biomea Fusion aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Biomea volatility, please check the breakdown of all its
fundamentals.
Are Biomea Fusion Earnings Expected to grow?
The
future earnings power of Biomea Fusion involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Biomea Fusion factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Biomea Fusion
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Biomea
expected earnings.
Biomea Fusion Gross Profit
Biomea Fusion Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Biomea Fusion previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Biomea Fusion Gross Profit growth over the last 10 years. Please check Biomea Fusion's
gross profit and other
fundamental indicators for more details.
What is driving Biomea Fusion Investor Appetite?
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Biomea Fusion is not uncomon. Institutional investors typically avoid acquiring a high percentage of Biomea Fusion stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Biomea is distributed among investors.
Ownership Allocation
Biomea Fusion retains a total of 29.4 Million outstanding shares. Over half of Biomea Fusion outstanding shares are owned by
other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these
institutions are subject to different rules and regulation than regular investors in Biomea Fusion. Please watch out for any change in the
institutional holdings of Biomea Fusion as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently
losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
| Retail Investors14.03% | Insiders34.59% | Institutions51.38% |
| Retail Investors | 14.03 |
| Insiders | 34.59 |
| Institutions | 51.38 |
Over 3 percent rise for Biomea Fusion. What does it mean for investors?
Current treynor ratio is at -1.04. Biomea Fusion exhibits very low volatility with skewness of 0.11 and kurtosis of 0.13. However, we advise investors to further study Biomea Fusion technical indicators to ensure that all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biomea Fusion's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biomea Fusion's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Conclusion on Biomea Fusion
Whereas some companies under the biotechnology industry are still a bit expensive, Biomea Fusion may offer a potential longer-term growth to investors. On the whole, as of the 17th of December 2022, our analysis shows that Biomea Fusion follows the market closely. The company is
undervalued and projects
low odds of financial distress for the next 2 years. However, our current 90 days buy-hold-sell recommendation on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Biomea Fusion. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com